What are the side effects of Degranol
SIDE-EFFECTS AND SPECIAL PRECAUTIONS:
Medical supervision during treatment is essential.
The level of serum folic acid should be observed during anticonvulsant therapy since Degranol may enhance the metabolism of folic acid.
Abnormalities of liver function and jaundice have been associated with long-term treatment.
Blood counts and liver function tests should be performed before commencing treatment.
Blood counts should then be repeated at weekly intervals during the first month of treatment and subsequently at monthly intervals; liver function tests should also be undertaken periodically, if allergic skin reactions occur, if the leucocyte and/or platelet count diminish, if tests reveal a deterioration in liver function, or if any serious adverse symptoms develop, Degranol should be withdrawn.
Reaction-time may be increased by Degranol. The patient's safety as a road-user or operator of machines may be impaired in consequence.
Unwanted effects - i.e. loss of appetite, dryness of the mouth, retching, diarrhoea or constipation, headache, drowsiness, dizziness, somnolence, ataxia, disorders of visual accommodation, diplopia, or, in elderly patients, states of confusion and agitation - may occur, particularly at the start of treatment. These effects may require temporary reduction in the dosage.
Hyponatraemia due to the antidiuretic effect of Degranol and possibly accompanied by vomiting, headache, and mental confusion has been observed.
Allergic skin reactions, as well as occurrences of exfoliative dermatitis, paraesthesia, systemic lupus erythematosus, Steven's-Johnson syndrome, photosensitivity, altered skin pigmentation, leucopenia, thrombocytopenia, agranulocytosis, aplastic anaemia, thrombo-embolism, left ventricular failure, disturbances of cardiac impulse conduction, hepatocellular and cholestatic hepatitis, acute oliguria with hypertension and proteinuria have been reported.
A wide variety of other central nervous system, gastro-intestinal, cardiovascular and dermatological effects have also been reported.
In patients with cardiovascular diseases, or with hepatic or renal disorders, glaucoma and in elderly subjects, Degranol should be administered with caution.
Tolerance may develop to some of the untoward effects of carbamazepine and they can be minimized by gradual increase in dosage and adjustment of maintenance dosage.
If treatment with Degranol is withdrawn abruptly, the change-over to another anti-epileptic should be effected under cover of diazepam or a barbiturate.